OSLO, Norway, July 1, 2021 /PRNewswire/ -- Targovax
ASA (OSE: TRVX) announces the appointment of Dr
Lone Ottesen, MD, PhD as Chief
Development Officer (CDO). She will take a leading role in driving
the clinical programs forward. Dr Ottesen will serve as a member of
Targovax's management team.
Dr Ottesen is a highly experienced drug developer
with extensive experience across the global oncology and
immune-oncology drug development spectrum with nearly 20 years
in the pharmaceutical industry in both early- and late-phase
development. Lone got her MD and PhD at Aarhus University in
Denmark and has held roles of
increasing seniority in GSK, Eisai and latest AstraZeneca where she
was the Global Clinical Head for two assets in
pivotal clinical development as well as leading the
development of durvalumab in breast and gynecological cancers. Lone
will be spearheading the clinical development program for the
Targovax portfolio including the planned registration-directed
trial in anti-PD1 refractory melanoma for the lead asset
ONCOS-102.
Oystein Soug, CEO,
commented: "It is with great enthusiasm that we welcome
Dr Ottesen to Targovax! As we have completed our early-stage
clinical development program and are entering into later stage
programs taking ONCOS-102 to market, her broad and deep drug
development experience will be instrumental in shaping Targovax's
future. We are proud to have attracted a seasoned expert like Lone,
and I am confident that she will be a valuable addition to our
team."
Dr Ottesen added: "I am excited to join Targovax at such
an important stage for the company. The clinical data with
ONCOS-102 in both monotherapy and in combination therapies in
several tumor types are impressive. I am very enthusiastic about
the path ahead with the potential for a registrational-directed
trial and the opportunity to broaden the development program into
other solid tumors. I look forward to start working with the strong
team at Targovax to build and execute the clinical program and
bring this promising therapy to patients.
Dr Ottesen commences as Chief Development Officer 1 July.
For further information, please contact:
Oystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa-appoints-dr-lone-ottesen-as-chief-development-officer,c3377934
